Opthea Ltd ADR OPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OPT is a good fit for your portfolio.
News
-
Opthea to Present at the OIS Retina Innovation Summit at ARVO
-
Opthea Appoints John Han, PharmD, as VP Medical Affairs
-
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
-
Opthea Appoints Sujal Shah to the Board of Directors
-
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
-
Opthea to Participate in the Leerink Partners Global Biopharma Conference
-
Opthea Reports Half-Year Financial Results and Business Updates
-
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Trading Information
- Previous Close Price
- $3.43
- Day Range
- $3.43–3.65
- 52-Week Range
- $1.60–4.42
- Bid/Ask
- $3.30 / $5.00
- Market Cap
- $300.75 Mil
- Volume/Avg
- 5,867 / 20,834
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,948.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.opthea.com
Comparables
Valuation
|
Metric
|
OPT
|
MSB
|
PAR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 0.11 | — |
Price/Book Value | — | 1.24 | 2.96 |
Price/Sales | 1,948.86 | 68.20 | 2,035.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
OPT
MSB
PAR
Financial Strength
|
Metric
|
OPT
|
MSB
|
PAR
|
|---|---|---|---|
Quick Ratio | 5.00 | 2.59 | 3.83 |
Current Ratio | 5.10 | 2.71 | 3.83 |
Interest Coverage | −7.52 | −2.96 | −4,970.13 |
Quick Ratio
OPT
MSB
PAR
Profitability
|
Metric
|
OPT
|
MSB
|
PAR
|
|---|---|---|---|
Return on Assets (Normalized) | −112.50% | −11.71% | −101.92% |
Return on Equity (Normalized) | −12,742.05% | −15.62% | −126.88% |
Return on Invested Capital (Normalized) | −10,051.29% | −9.87% | −128.45% |
Return on Assets
OPT
MSB
PAR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nxxfwbqz | Zyn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sgtqhdrr | Fxldbpr | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jbghqrpm | Pxldx | $97.8 Bil | |
MRNA
| Moderna Inc | Syygpvwp | Zjzck | $38.8 Bil | |
ARGX
| argenx SE ADR | Nczbqhvcd | Bcx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Yfjfwhqm | Qcxg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sxdkyzbc | Tmxhvd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lrwqjyrk | Xvgby | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvxpdybrgc | Dzvtd | $12.5 Bil | |
INCY
| Incyte Corp | Vpdlknjp | Mdxzhn | $11.5 Bil |